血清miR-296-3p和miR-324-3p表达与肾癌患者临床病理特征及预后的关系

Relationship between serum miR-296-3p and miR-324-3p expression and clinical pathological features and prognosis of renal cell carcinoma patients

目的:分析血清微小核糖核酸-296-3p(microribonucleic acid-296-3p,miR-296-3p)和微小核糖核酸-324-3p(microribonucleic acid-324-3p,miR-324-3p)表达水平与肾癌患者临床病理特征及预后的关系。方法:选择2017年1月—2020年12月广安市人民医院收治的90例肾癌患者(肾癌组),另选择同时期本院收治的90例肾良性病变患者(良性组),同时期来院接受体检的90例健康体检者(健康组);采用实时荧光定量PCR(RT-PCR)法检测血清中miR-296-3p和miR-324-3p的相对表达量;采用Cox回归分析影响肾癌患者预后的因素;采用Kaplan-Meier生存曲线分析miR-296-3p、miR-324-3p水平与肾癌患者预后的关系。结果:健康组、良性组、肾癌组血清miR-296-3p水平依次升高(P<0.05),miR-324-3p水平依次降低(P<0.05)。miR-296-3p高表达患者TNM分期为Ⅲ~Ⅳ期的例数显著高于miR-296-3p低表达患者(P<0.05);miR-324-3p低表达患者TNM分期为Ⅲ~Ⅳ期的例数显著高于miR-324-3p高表达患者(P<0.05)。生存组miR-296-3p水平显著低于死亡组,miR-324-3p水平显著高于死亡组(P<0.05)。TNM分期、miR-296-3p、miR-324-3p是影响肾癌患者生存或死亡的因素(P<0.05)。miR-296-3p高表达患者3年总生存率(43.75%,21/48)显著低于miR-296-3p低表达患者(95.24%,40/42)(χ^(2)=28.471,P<0.001);miR-324-3p低表达患者3年总生存率(43.48%,20/46)显著低于miR-324-3p高表达患者(93.18%,41/44)(χ^(2)=27.768,P<0.001)。结论:肾癌患者血清miR-296-3p水平显著升高,miR-324-3p水平显著降低,且与肾癌患者临床病理特征以及预后相关。

Objective To analyze the relationship between the expression levels of serum microribonucleic acid-296-3p (miR-296-3p), microribonucleic acid-324-3p (miR-324-3p) and the clinical pathological features, prognosis of renal cell carcinoma patients.Methods A total of 90 renal cancer patients(renal cancer group) admitted to Guang'an People's Hospital from January 2017 to December 2020 were selected. Additionally, 90 patients with benign renal lesions(benign group) admitted to our hospital were selected, and 90 healthy individuals(healthy group) who underwent physical examinations at our hospital during the same period were collected. Real-time fluorescence quantitative PCR(RT-PCR) method was applied to detect the relative expression levels of miR-296-3p and miR-324-3p in serum. Cox regression was applied to analyze the factors affecting the prognosis of renal cancer patients. Kaplan-Meier survival curve was applied to analyze the relationship between miR-296-3p, miR-324-3p levels and the prognosis of renal cancer patients.Results The serum miR-296-3p level in the healthy group, benign group, and renal cancer group increased sequentially(P < 0.05), while the miR-324-3p level decreased sequentially(P < 0.05). The number of TNM stage Ⅲ-Ⅳ in patients with high expression of miR-296-3p was obviously higher than those in patients with low expression of miR-296-3p(P < 0.05). The number of TNM stage Ⅲ-Ⅳ in patients with low expression of miR-324-3p was obviously higher than that in patients with high expression of miR-324-3p(P < 0.05). The miR-296-3p level in the survival group was obviously lower than that in the death group, while the miR-324-3p level was obviously higher than that in the death group(P < 0.05). TNM staging, miR-296-3p, and miR-324-3p were factors that affected the survival or death of renal cancer patients(P < 0.05). The 3-year overall survival rate(43.75%, 21/48) of patients with high expression of miR-296-3p was obviously lower than that of patients with low expression of miR-296-3p(95.24%, 40/42)(χ^(2)=28.471, P < 0.001). The 3-year overall survival rate of patients with low expression of miR-324-3p(43.48%, 20/46) was obviously lower than that of patients with high expression of miR-324-3p(93.18%, 41/44)(χ^(2)=27.768, P < 0.001).Conclusion High level of serum miR-296-3p and low level of serum miR-324-3p are associated with the clinical pathological features and prognosis of renal cancer patients.